

*SOURCE: Neptune Technologies & Bioresources Inc.*

## **Jim Hamilton Officially Starts at Neptune**

*Seasoned leader in development, manufacturing, marketing and sales of nutraceutical products*

**Laval, Québec, CANADA – February 3, 2015** – Neptune Technologies & Bioresources Inc. (“Neptune” or the “Corporation”) (NASDAQ.NEPT - TSX.NTB), announces that on February 2, 2015 Mr. Jim Hamilton officially started as Neptune’s President and CEO.

“Jim has a deep understanding of the nutraceutical space, strong industry connections and a proven track record for driving business excellence,” highlighted Mr. Pierre Fitzgibbon, Chairman of Neptune’s Board of Directors. “He brings complementary abilities to the current management team and he is the right person to lead the Corporation forward into its next phase of growth and success.”

“I am very excited, both professionally and personally, to be joining Neptune,” highlighted Mr. Hamilton. “Having worked in the nutrition industry for 30 years, I am well aware of the health benefits nutraceutical products provide. In this respect, I have a special interest in omega-3’s and omega-3 krill oils in particular, which offer a number of differentiated benefits.”

“Neptune pioneered the krill oil market, and its flagship product Neptune Krill Oil (NKO®) offers superior levels of phospholipids and omega-3 combinations,” continued Mr. Hamilton. “I have watched Neptune over the years and have been particularly impressed by the strategic steps they have taken in recent history to enhance their business model and put in place the necessary ingredients for success. I look forward to working together with Neptune’s Board and management team as we continue to solidify the business and reaffirm our role as a premier krill oil manufacturer.”

### **About Neptune Technologies & Bioresources Inc.**

Neptune is a biotechnology company engaged primarily in the development and commercialization of marine-derived omega-3 polyunsaturated fatty acids (“PUFAs”). Neptune has a patented process of extracting oils from Antarctic krill, and principally sells omega-3 PUFAs as bulk oil to Neptune’s distributors who commercialize them under their private label primarily in the U.S., European and Australian nutraceutical markets. Neptune’s products generally come in bulk oil or capsule form and serve as a dietary supplement to consumers. Neptune’s head office is located at 545 Promenade du Centropolis, Suite 100, Laval, Quebec.

Neptune holds approximately 48% of the participating and voting rights of Acasti Pharma Inc. (“Acasti”) and 95% of the voting rights of NeuroBioPharm Inc. (“NeuroBio”). Through these subsidiaries, Neptune is also pursuing opportunities in the medical food and prescription drug markets. Acasti and NeuroBioPharm respectively focus on the research and development of safe and therapeutically effective compounds for highly prevalent atherosclerotic conditions, such as cardiometabolic disorders and cardiovascular diseases, and for neurodegenerative and inflammation related conditions. Acasti’s lead prescription drug candidate is CaPre®, a purified high omega-3 phospholipid concentrate derived from Neptune krill oil being developed to address the prevention and treatment of cardiometabolic disorders, including hypertriglyceridemia, which is characterized by abnormally high levels of triglycerides.

## **Forward Looking Statements**

*Statements in this press release that are not statements of historical or current fact constitute “forward-looking statements” within the meaning of the U.S. securities laws and Canadian securities laws. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of Neptune to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “will,” or “plans” to be uncertain and forward-looking. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.*

*The forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement and the “Cautionary Note Regarding Forward-Looking Information” section contained in Neptune’s latest Annual Information Form, which also forms part of Neptune’s latest annual report on Form 40-F, and which is available on SEDAR at [www.sedar.com](http://www.sedar.com), on EDGAR at [www.sec.gov/edgar.shtml](http://www.sec.gov/edgar.shtml) and on the investor section of Neptune’s website at [www.neptunebiotech.com](http://www.neptunebiotech.com) (the “AIF”). All forward-looking statements in this press release are made as of the date of this press release. Neptune does not undertake to update any such forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in Neptune public securities filings with the Securities and Exchange Commission and the Canadian securities commissions. Additional information about these assumptions and risks and uncertainties is contained in the AIF under “Risk Factors”.*

*Neither NASDAQ nor the Toronto Stock Exchange accepts responsibility for the adequacy or accuracy of this release.*

### **Neptune Contacts:**

André Godin  
Chief Financial Officer  
+1.450.687.2262  
[a.godin@neptunebiotech.com](mailto:a.godin@neptunebiotech.com)  
[neptunebiotech.com](http://neptunebiotech.com)

John Ripplinger  
Investor Relations  
+1.450.687.2262  
[j.riplinger@neptunebiotech.com](mailto:j.riplinger@neptunebiotech.com)  
[neptunebiotech.com](http://neptunebiotech.com)